Literature DB >> 12880423

Molecular and functional bases of self-antigen recognition in long-term persistent melanocyte-specific CD8+ T cells in one vitiligo patient.

Stefania Mantovani1, Silvia Garbelli, Belinda Palermo, Rita Campanelli, Valeria Brazzelli, Giovanni Borroni, Myriam Martinetti, Federica Benvenuto, Giampaolo Merlini, Gioacchino Robustelli della Cuna, Licia Rivoltini, Claudia Giachino.   

Abstract

Vitiligo patients possess high frequencies of circulating CD8+ T lymphocytes specific for the melanocyte differentiation antigen Melan-A/MART-1. These self-specific T cells exhibit intact functional properties and their T cell receptors are selected for a narrow range of high affinities of antigen recognition, suggesting their important role in the pathogenesis of vitiligo. In order to understand the molecular base for this unexpected, optimal T cell receptor recognition of a self-antigen, a tetramer-guided ex vivo analysis of the T cell receptor repertoire specific for the Melan-A antigen in a patient affected by vitiligo is reported. All T cell receptors sequenced corresponded to different clonotypes, excluding extensive clonal expansions and revealing a large repertoire of circulating Melan-A-specific T lymphocytes. A certain degree of T cell receptor structural conservation was noticed, however, as a single AV segment contributed to the alpha chain rearrangement in 100% of clones and a conserved amino acid sequence was found in the beta chain complementarity determining region 3 of various high affinity cells. We suggest that the conserved alpha chain confers self-antigen recognition, necessary for intrathymic selection and peripheral homeostasis, to many synonymous T cell receptors, whereas the beta chain fine tunes the T cell receptor affinity of the specific cells. In addition, we demonstrate that many high avidity T cell clones from this patient were capable of specifically lysing normal, HLA-matched melanocytes. These autoreactive clones persisted for more than 3 y in the patient's peripheral blood. These data, together with the skin-homing potential of the clones, directly point to the in vivo pathogenic role of melanocyte-specific cytotoxic T lymphocytes in vitiligo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12880423     DOI: 10.1046/j.1523-1747.2003.12368.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  8 in total

1.  Transgenic mice with a diverse human T cell antigen receptor repertoire.

Authors:  Liang-Ping Li; J Christoph Lampert; Xiaojing Chen; Catarina Leitao; Jelena Popović; Werner Müller; Thomas Blankenstein
Journal:  Nat Med       Date:  2010-08-08       Impact factor: 53.440

2.  Th17 cells and activated dendritic cells are increased in vitiligo lesions.

Authors:  Claire Q F Wang; Andres E Cruz-Inigo; Judilyn Fuentes-Duculan; Dariush Moussai; Nicholas Gulati; Mary Sullivan-Whalen; Patricia Gilleaudeau; Jules A Cohen; James G Krueger
Journal:  PLoS One       Date:  2011-04-25       Impact factor: 3.240

3.  Hypothesis: zinc can be effective in treatment of vitiligo.

Authors:  Nooshin Bagherani; Reza Yaghoobi; Mohammad Omidian
Journal:  Indian J Dermatol       Date:  2011 Sep-Oct       Impact factor: 1.494

4.  Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity.

Authors:  Leeann T Blalock; Jennifer Landsberg; Michelle Messmer; Jian Shi; Angela D Pardee; Ronald Haskell; Lazar Vujanovic; John M Kirkwood; Lisa H Butterfield
Journal:  Oncoimmunology       Date:  2012-05-01       Impact factor: 8.110

5.  Transfer of efficient anti-melanocyte T cells from vitiligo donors to melanoma patients as a novel immunotherapeutical strategy.

Authors:  Belinda Palermo; Silvia Garbelli; Stefania Mantovani; Claudia Giachino
Journal:  J Autoimmune Dis       Date:  2005-08-31

6.  Phenytoin as a novel anti-vitiligo weapon.

Authors:  M R Namazi
Journal:  J Autoimmune Dis       Date:  2005-11-22

7.  Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.

Authors:  Federico Serana; Alessandra Sottini; Luigi Caimi; Belinda Palermo; Pier Giorgio Natali; Paola Nisticò; Luisa Imberti
Journal:  J Transl Med       Date:  2009-03-24       Impact factor: 5.531

8.  T-cell clonotypes in cancer.

Authors:  Per Thor Straten; David Schrama; Mads Hald Andersen; Jürgen C Becker
Journal:  J Transl Med       Date:  2004-04-08       Impact factor: 5.531

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.